-
Je něco špatně v tomto záznamu ?
Recent advances in the design and synthesis of prednisolone and methylprednisolone conjugates
E. Bílková, A. Imramovský, M. Sedlák
Jazyk angličtina Země Nizozemsko
Typ dokumentu časopisecké články, přehledy
- MeSH
- antiflogistika aplikace a dávkování škodlivé účinky chemická syntéza chemie MeSH
- lidé MeSH
- methylprednisolon aplikace a dávkování škodlivé účinky analogy a deriváty chemická syntéza chemie MeSH
- molekulární struktura MeSH
- molekulová hmotnost MeSH
- prednisolon aplikace a dávkování škodlivé účinky analogy a deriváty chemická syntéza chemie MeSH
- prekurzory léčiv aplikace a dávkování škodlivé účinky chemická syntéza chemie MeSH
- racionální návrh léčiv MeSH
- systémy cílené aplikace léků MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
Glucocorticoid drugs are commonly used in the treatment of many acute and chronic inflammatory diseases. However, application of these steroids is limited because of their physico-chemical properties, such as very low water solubility. Glucocorticoids also exhibit serious adverse side effects. Therefore, new drug delivery systems are being developed, with the aim of improving the physicochemical properties of glucocorticoids while avoiding undesirable side effects associated with systemic administration. Here we discuss the design and synthesis of conjugates of prednisolone (PD), methylprednisolone (MPD) and similar glucocorticoids. In this review, possibilities for targeting inflammatory sites, and reducing dosages and administration frequency through increasing drug circulation time are discussed. This review summarises synthetic approaches for the preparation of covalent conjugates, which are divided into two groups: low molecular weight conjugates and polymeric conjugates. These two groups are further divided into subgroups based on the chemical structure of the conjugates. Published results from in vitro and in vivo testing of prepared conjugates are also discussed.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc12022206
- 003
- CZ-PrNML
- 005
- 20160308082835.0
- 007
- ta
- 008
- 120806s2011 ne f 000 0#eng||
- 009
- AR
- 024 7_
- $a 10.2174/138161211798194530 $2 doi
- 035 __
- $a (PubMed)22074428
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Bílková, Eliška. $7 _AN058800 $u Institute of Organic Chemistry and Technology, Faculty of Chemical Technology, University of Pardubice, Studentská 573, 532 10 Pardubice, Czech Republic
- 245 10
- $a Recent advances in the design and synthesis of prednisolone and methylprednisolone conjugates / $c E. Bílková, A. Imramovský, M. Sedlák
- 520 9_
- $a Glucocorticoid drugs are commonly used in the treatment of many acute and chronic inflammatory diseases. However, application of these steroids is limited because of their physico-chemical properties, such as very low water solubility. Glucocorticoids also exhibit serious adverse side effects. Therefore, new drug delivery systems are being developed, with the aim of improving the physicochemical properties of glucocorticoids while avoiding undesirable side effects associated with systemic administration. Here we discuss the design and synthesis of conjugates of prednisolone (PD), methylprednisolone (MPD) and similar glucocorticoids. In this review, possibilities for targeting inflammatory sites, and reducing dosages and administration frequency through increasing drug circulation time are discussed. This review summarises synthetic approaches for the preparation of covalent conjugates, which are divided into two groups: low molecular weight conjugates and polymeric conjugates. These two groups are further divided into subgroups based on the chemical structure of the conjugates. Published results from in vitro and in vivo testing of prepared conjugates are also discussed.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a antiflogistika $x aplikace a dávkování $x škodlivé účinky $x chemická syntéza $x chemie $7 D000893
- 650 _2
- $a systémy cílené aplikace léků $7 D016503
- 650 _2
- $a racionální návrh léčiv $7 D015195
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a methylprednisolon $x aplikace a dávkování $x škodlivé účinky $x analogy a deriváty $x chemická syntéza $x chemie $7 D008775
- 650 _2
- $a molekulární struktura $7 D015394
- 650 _2
- $a molekulová hmotnost $7 D008970
- 650 _2
- $a prednisolon $x aplikace a dávkování $x škodlivé účinky $x analogy a deriváty $x chemická syntéza $x chemie $7 D011239
- 650 _2
- $a prekurzory léčiv $x aplikace a dávkování $x škodlivé účinky $x chemická syntéza $x chemie $7 D011355
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Imramovský, Aleš $7 xx0118877
- 700 1_
- $a Sedlák, Miloš, $d 1959- $7 ola2002159209
- 773 0_
- $w MED00007893 $t Current pharmaceutical design $x 1873-4286 $g Roč. 17, č. 32 (2011), s. 3577-3595
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/22074428 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y m $z 0
- 990 __
- $a 20120806 $b ABA008
- 991 __
- $a 20160308082850 $b ABA008
- 999 __
- $a ok $b bmc $g 944119 $s 779503
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2011 $b 17 $c 32 $d 3577-3595 $i 1873-4286 $m Current pharmaceutical design $n Curr Pharm Des $x MED00007893
- LZP __
- $b NLK111 $a Pubmed-20120806/12/01